Communiqués

21/09 Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01) BU
21/09 Strongest half-year in Curatis’s history — revenue up 51% and significant progress on corticorelin (C-PTBE-01) EQ
11/06 Curatis Increases Revenue Growth Guidance for 2026 EQ
11/06 Curatis Increases Revenue Growth Guidance for 2026 BU
22/05 Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors EQ
22/05 Curatis Holding AG announces CHF 3.0 million private placement with strategic investor EQ
24/03 Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved EQ
24/03 Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved BU
11/03 Curatis and Neupharma announce exclusive licensing agreement to develop and market corticorelin (C-PTBE-01) for the treatment of peritumoral brain edema in Japan EQ
11/03 Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan BU
25/11 Curatis : VALUATIONLAB PU
21/11 Curatis Holding AG announces CHF 1.2 million private placement with strategic investor EQ
18/09/25 FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3 EQ
18/09/25 Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 3 BU
15/09/25 Curatis : Half Year Report 2025 PU
15/09/25 Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01 EQ
15/09/25 Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01 BU
05/09/25 Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues EQ
05/09/25 Curatis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual Revenues BU
31/07/25 FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study EQ
24/05/25 Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors EQ
23/05/25 Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billion | Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog EQ
23/05/25 Curatis discloses Corticorelin as active substance of C-PTBE-01 BU
07/04/25 Curatis : VALUATIONLAB PU
27/03/25 Curatis: Umsatzwachstum von 30% im Vertrieb - dazu deutliche Ausweitung Patientenzielgruppe beim Lead-Projekt C-PTBE-01 EQ
Aucun résultat pour cette recherche